We are committed to serving the best interests of our shareholders. You will find key shareholder information and financial reports available to help put Neoleukin Therapeutics, Inc's financial performance into perspective.
July 2, 2020
July 1, 2020
June 22, 2020
Neoleukin Therapeutics Presents Preclinical Data for NL-201 and De Novo Protein Design Technology at American Association for Cancer Research (AACR) Virtual Annual Meeting II